Kindred Biosciences, Inc.
KIN
KIN was delisted on the 27th of August, 2021.
84 hedge funds and large institutions have $156M invested in Kindred Biosciences, Inc. in 2021 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 29 increasing their positions, 25 reducing their positions, and 10 closing their positions.
99% more call options, than puts
Call options by funds: $1.19M | Put options by funds: $599K
33% more capital invested
Capital invested by funds: $117M → $156M (+$39.1M)
20% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 10
16% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 25
7.03% more ownership
Funds ownership: 68.66% → 75.69% (+7%)
2% more funds holding
Funds holding: 82 → 84 (+2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$18.6M |
| 2 |
BCPEMI
Bain Capital Public Equity Management II
Boston,
Massachusetts
|
+$4.31M |
| 3 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
+$1.54M |
| 4 |
HM
HealthCor Management
New York
|
+$1.28M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1.05M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
Ariel Investments
Chicago,
Illinois
|
-$3.72M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$3.62M |
| 3 |
PWAM
Park West Asset Management
San Francisco,
California
|
-$1.03M |
| 4 |
Renaissance Technologies
New York
|
-$836K |
| 5 |
Morgan Stanley
New York
|
-$452K |
KIN Hedge Fund Activity: Q1 2021 in Review
84 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Kindred Biosciences, Inc. (KIN) for Q1 2021, worth a combined $156M — up 33% from $117M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new KIN positions and 10 closed out — a net gain of 2 holders — while 29 added to existing stakes and 25 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $18.6M. The largest seller was Ariel Investments, cutting an estimated $3.72M.
- 84 institutional investors held Kindred Biosciences, Inc. (KIN) as of Q1 2021, up from 82 in Q4 2020.
- Funds reported $156M of Kindred Biosciences, Inc. stock for Q1 2021, up 33% quarter-over-quarter.
- 12 funds opened new Kindred Biosciences, Inc. positions in Q1 2021 and 10 closed out, a net change of +2 holders.
- The largest Kindred Biosciences, Inc. buyer in Q1 2021 was Point72 Asset Management, an estimated $18.6M added.
- The largest Kindred Biosciences, Inc. seller in Q1 2021 was Ariel Investments, an estimated $3.72M sold.
Based on aggregated 13F filings for Q1 2021.